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INTRODUCTION:  Sickle cell disease is a group of haemoglobinopathies involving a point mutation in the β-haemoglobin gene. The most common 
and severe form is homozygous sickle cell anaemia (SCA). In the UK, SCA affects 1 in 2000 births1. Patients with SCA have increased risk of stroke 
and regular blood transfusions are commonplace to decrease stroke risk. Transfused patients are known to have iron overload, particularly in the 
liver2 and may receive iron chelation therapy. Tissue magnetic susceptibility (χ) derived by MRI susceptibility mapping has been shown to correlate 
strongly with tissue iron content3-5 and one study of transfused SCA patients6 has shown increased χ in some iron-rich deep-brain gray-matter 
regions. Therefore, we mapped the χ in SCA patients transfused (for reasons other than to prevent recurrent stroke) and healthy controls to test the 
hypothesis H1:  that iron content in deep-brain regions is higher in transfused SCA patients than in healthy controls. The iron content of deep-
brain regions in non-transfused SCA patients has not been studied so we mapped χ in a large cohort of non-transfused SCA patients and healthy 
controls. SCA patients have a lower haematocrit than healthy controls and are not orally supplemented with iron, therefore hypothesis H2:  is that 
the iron content in deep-brain regions is lower in non-transfused SCA patients than in healthy controls. Purpose:  It is clinically important to 
measure brain tissue iron content in SCA patients as this could inform their treatment in future. 
METHODS:  Cohort: 25 children and adults with SCA showing no evidence of cerebral infarction on T2-W MRI and 18 matched controls. Subjects 
with motion artifacts were excluded. Pilot study: To test H1 and H2 we selected all 5 patients treated with regular blood transfusions for 2-10 
(median 5) years for severe disease e.g. frequent pain. We also included 5 age-, gender- and race-matched SCA patients not on any treatment and 5 
similarly matched healthy controls. The mean/(range) of ages were 18.3/(10.9-28.4), 16.8/(10.1-29.4) and 17.8/(9.6-27.8) for transfused, healthy and 
non-transfused groups respectively. Each group of 5 had 2 females. Larger study: H2 was tested further in 20 non-transfused SCA patients (11F) and 
18 controls (9F). The groups had very similar age distributions: mean/SD = 15.3/6.6 v. 14.8/5.7 in patients v. controls. MRI Acquisitions: Images 
were acquired on a clinical 1.5 T Siemens system with a 32-channel RF coil. The 3D gradient echo sequence had parameters: TR = 40 ms, α = 25°, 5 
echoes: TE1 = 4.94 ms, ΔTE = 7.35 ms, FoV = 256 x 176 x 120 mm, 1 mm isotropic resolution, GRAPPA acceleration x 3 in the PE direction with 
24 reference lines, 7/8 partial Fourier acquisition in both PE directions, BW = 140 Hz/pix and total acquisition time = 5 mins 44 s. A T1-W image 
was also acquired using a 3D FLASH sequence (TR = 11ms, TE= 4.94ms, α = 15°, 1 mm isotropic resolution) to allow automated region-of-interest 
(ROI) segmentation. Image Processing: For each subject, complex images from all 5 TEs were fitted7 to generate a ΔB map. Residual phase wraps 
and some background fields were removed by Laplacian unwrapping8 using a FSL BET brain mask (no. erodes = 3, TSVD threshold = 0.02). 
Residual background fields were removed using SHARP4 with a spherical kernel radius = 1 mm at the edge of the brain to 20 mm at the centre9. χ 
mapping used a TKD technique3 (t = 1.5 to minimise streaking artifacts) and underestimation of χ was corrected by dividing by 0.358. R2* maps were 
calculated by a linear fit of log(magnitude) values over all 5 TEs as a reference. ROI Analysis and Statistics: The T1-W image was co-registered to 
the T2*-W magnitude image using FSL FLIRT. FSL FIRST was applied to the co-registered T1-W images to segment left and right caudate (CN), 
putamen (PT) and globus pallidus (GP) ROIs for each subject (e.g. see Fig 1). The ROIs were applied to yield mean χ and R2* for each ROI in each 
subject. For each study, ANCOVA statistics were used to investigate differences in ROI mean χ and R2* values between groups, controlling for age, 
gender and any interaction between age and gender. Post-hoc t-tests were used to investigate significant differences between groups. 
RESULTS:  An example χ map from a non-transfused SCA patient is shown in Fig. 2. The GP is bright as it has high iron content. Pilot study: Table 
1 shows the mean and standard deviation (SD) of the χ values in each group and ROI and ANCOVA results. There were no significant effects on χ of 
age or gender. There was a significantly lower χ in the GP in both SCA patient groups than in controls. An ANCOVA on the R2* values showed no 
significant differences by group or gender but showed highly significant positive correlations of R2* with age (p < 0.018). Larger study: Similar 
mean χ and R2* values were obtained. There was a trend for lower GP χ in SCA. The ANCOVA on the χ values showed no significant effects except 
for a significant positive correlation of CN χ with age (p = 0.003). An ANCOVA on the R2* values showed no significant effects of group or gender 
but showed highly significant positive correlations of R2* with age (p < 0.00024) as well as some significant effects of gender × age interactions. 
Table 1. Pilot Study     ROI Caudate Globus Pallidus Putamen 
Susceptibility (x 10-2 ppm) Mean SD Mean SD Mean SD 
Healthy Control 1.95 0.52 6.50 1.17 -0.25 0.53 
Non-Transfused SCA 1.39 0.59 4.46 1.14 0.11 0.46 
Transfused SCA 1.98 0.50 4.69 1.01 -0.11 0.45 
ANOVA F (p) – Group 2.28 (0.16) 6.68 (0.02a,b) 1.30 (0.32) 
DISCUSSION AND CONCLUSIONS:  In this cohort, the ROI mean χ values are similar to but lower than in previous studies in 
haemoglobinopathy patients6,10 probably because those studies measured only positive χ values within each ROI whereas all (both positive and 
negative) values were included here. The SD of ROI χ values is similar to previous studies6,10. The pilot study showed a significantly lower χ in the 
GP in both SCA patient groups than in controls. Transfused patients did not have high χ . This supports H2 and agrees with the lower χ values found 
in the GP of β-thalassaemia patients compared with controls10. The lack of significant results in the larger study does not provide strong evidence to 
support H2 although there was a trend to lower χ in the GP of SCA patients. An increase in the cohort size, including patients with infarction, would 
allow further investigation. Significant positive correlations were found between R2* values and age as expected11. The lack of significant positive 
correlations of χ with age12 - except in the CN - is probably due to the relatively low SNR phase and χ maps. Several ΔB and χ maps showed an 
artifact due to open-ended fringe lines in the original phase images. This may be overcome by improved combination of the multiple RF coil data13. 
In future, we intend to investigate other ROIs including the choroid plexus, red nucleus and substantia nigra. The suggestion of decreased iron content 
in the GP in SCA patients is clinically important as, if proven, it may explain some cognitive deficits and affect patient treatment. 
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Figure 1. ROIs in the 
CN (red), PT (yellow) 
and GP (aqua) on the χ 
map of a transfused 
SCA patient. Figure 2.          χ map in a 
non-transfused 
SCA patient.  
t-tests: a: Controls > Non-transfused 
SCA (p = 0.014)  b: Controls > 
Transfused SCA (p = 0.015) 
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